# Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Source: https://onco.cc/trials/nct04668690/  
OnCo record `nct04668690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Mitoxantrone and Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.

## Summary

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL is a phase 3 interventional study registered as NCT04668690 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 193 participants enrolled, started 2021-04-13 and due to reach its primary completion in 2027-12-30. Interventions recorded: Mitoxantrone Hydrochloride Liposome Injection and Chidamide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04668690
- Phase: 3
- Setting: A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL.
- Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrolled: 193

## Sources

- ClinicalTrials.gov NCT04668690: https://clinicaltrials.gov/study/NCT04668690

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Mitoxantrone](https://onco.cc/drugs/mitoxantrone/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct04668690.json